CBER’s New Director 'Marks' New Era For Biologics Regulation
This article was originally published in The Pink Sheet Daily
Peter Marks takes over top spot in FDA's center for biologics after four-year training period as deputy director; his background appears well suited to what promises to be a transformative era in medicine.
You may also be interested in...
Director Peter Marks makes his mark in shuffling of office divisions aimed at regulatory efficiency.
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.